Quarterly report pursuant to Section 13 or 15(d)

Balance Sheets

v3.5.0.1
Balance Sheets - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Current Assets:    
Cash and cash equivalents $ 259,663 $ 28,091
Note receivable - Moleculin, LLC 30,000 0
Total Assets 289,663 28,091
Current Liabilities:    
Accounts payable and accrued expenses 363,003 322,790
Convertible notes payable 615,000 450,000
Total Liabilities $ 978,003 $ 772,790
Commitments and contingencies
Stockholders' Deficit:    
Common stock, $0.001 par value; 20,000,000 authorized, 6,789,833 and 6,661,000 shares issued and outstanding, respectively $ 6,790 $ 6,661
Subscription receivable (3,000) (3,000)
Additional paid-in capital 388,471 0
Accumulated deficit (1,080,601) (748,360)
Total Stockholders' Deficit (688,340) (744,699)
Total Liabilities and Stockholders' Deficit $ 289,663 $ 28,091